| EMEA CTEPH Registry: An international prospective registry investigating the epidemiology, diagnosis and treatment of CTEPH patients in EMEA countries. |
Ongoing |
Riociguat |
4 |
18303 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh), Prince Sultan Military Medical City (Riyadh) |
| EXPERT, EXPosurE Registry RiociguaT in patients with pulmonary hypertension |
Ongoing |
Riociguat |
4 |
16657 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh), Prince Sultan Military Medical City (Riyadh) |
| A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease |
Terminated |
Finerenone |
3 |
BAY 94-8862 16244 |
King Abdulaziz University Hospital (Jeddah) |
| A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care(FIGARO -DKD) |
Terminated |
Finerenone |
3 |
BAY 94-8862 17530 |
King Abdulaziz University Hospital (Jeddah) |
| "A randomized, double-blind Phase III study of copanlisib versusplacebo in patients with rituximab-refractory indolent non-Hodgkin’slymphoma (iNHL) – CHRONOS-2" |
Terminated |
BAY 80-6946/Copanlisib |
3 |
BAY 80-6946 / 17322 |
King Abdulaziz University Hospital (Jeddah), King Abdullah Medical City (Makkah), King Fahad Specialist Hospital (Dammam) |
| A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) |
Ongoing |
MEDI4736+Tremelimumab |
3 |
D419AC00003 |
King Khalid University Hospital (Riyadh), King Fahad Specialist Hospital (Dammam) |
| Single arm Phase I/II study of the safety, tolerability and efficacy of the investigational anti PD-L1 monoclonal antibody Durvalumab in combination with Paclitaxel in patients with metastatic triple negative PD-L1 positive breast cancer |
Ongoing |
MEDI4736/Paclitaxel |
2 |
ESR-14-10649 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| RIFTOS MKI - Radioactive Iodine reFractory asymptomatic patients in differentiated Thyroid cancer – an Observational Study to assess the use of MultiKinase Inhibitors |
Ongoing |
Nexavar (Sorafenib) |
4 |
17852 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Randomized, three- way, three- period, single oral dose, open-label, crossover, bioequivalence study to compare Lorvast Tablets /Tabuk Pharmaceutical Mfg. Co. (20 mg Atorvastatin), versus Lipitor® (20 mg Atorvastatin) Produced by Pfizer in healthy subjects under fasting conditions. |
Completed |
Lipitor® lovarst tablet |
4 |
42370 |
saudi Ajal |
| SAUDI ARABIA – A DISEASE REGISTRY STUDY TO PROSPECTIVELY OBSERVE TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH HER2-POSITIVE UNRESECTABLE LOCALLY ADVANCED OR METASTATIC BREAST CANCER |
Ongoing |
N/A |
4 |
ML29618 |
King Abdulaziz Medical City NG (Riyadh) |
